Protein biomarkers of new-onset cardiovascular disease: Prospective study from the systems approach to biomarker research in cardiovascular disease initiative

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 4, 2014, Pages 939-945

  Yin, Xiaoyan ^a,b   Subramanian, Subha ^a,c   Hwang, Shih Jen ^a,c   O'Donnell, Christopher J ^a,c   Fox, Caroline S ^a,c   Courchesne, Paul ^a   Muntendam, Pieter ^d   Gordon, Neal ^d   Adourian, Aram ^d   Juhasz, Peter ^d   Larson, Martin G ^b,e   Levy, Daniel ^a,c,f  

^a FRAMINGHAM HEART STUDY   (United States)

^b BOSTON UNIVERSITY   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d BG Medicine Inc   (United States)

^e USA   (United States)

^f BOSTON MEDICAL CENTER   (United States)

Author keywords

biological markers; cardiovascular diseases; epidemiology; myocardial infarction; proteomics

Indexed keywords

ALBUMIN; ALPHA AMYLASE SALIVA ISOENZYME; AMYLOID A PROTEIN; ARYLDIALKYLPHOSPHATASE 1; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD146 ANTIGEN; CD5 ANTIGEN; CELL SURFACE PROTEIN; COLLAGEN TYPE 1; CONTACTIN 1; CYCLOPHILIN A; GELSOLIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MULTIMERIN 2; MYOGLOBIN; NERVE CELL ADHESION MOLECULE; OROSOMUCOID; PLASMA PROTEIN; PROTEIN KINASE C; TETRANECTIN; UNCLASSIFIED DRUG;

AGED; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REVIEW; SMOKING; SYSTOLIC BLOOD PRESSURE;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; EPIDEMIOLOGY; MYOCARDIAL INFARCTION; PROTEOMICS;

AGED; BIOLOGICAL MARKERS; BLOOD PROTEINS; CASE-CONTROL STUDIES; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; INCIDENCE; MALE; MASS SPECTROMETRY; MASSACHUSETTS; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; PROSPECTIVE STUDIES; PROTEOMICS; RISK ASSESSMENT; RISK FACTORS; SYSTEMS BIOLOGY;

EID: 84897450955     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.302918     Document Type: Review

References (27)

1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367:1747-1757.
2. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847.
3. Wang TJ, Gona P, Larson MG, Tofer GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D'Agostino RB, Vasan RS. Multiple biomarkers for the prediction of frst major cardiovascular events and death. N Engl J Med. 2006;355:2631-2639.
4. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004;350:655-663.
5. Ware JH. The limitations of risk factors as prognostic tools. N Engl J Med. 2006;355:2615-2617.
6. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49:1373-1379.
7. Prentice RL, Paczesny S, Aragaki A, et al. Novel proteins associated with risk for coronary heart disease or stroke among postmenopausal women identifed by in-depth plasma proteome profling. Genome Med. 2010;2:48.
8. Satoh K, Matoba T, Suzuki J, O'Dell MR, Nigro P, Cui Z, Mohan A, Pan S, Li L, Jin ZG, Yan C, Abe J, Berk BC. Cyclophilin A mediates vascular remodeling by promoting infammation and vascular smooth muscle cell proliferation. Circulation. 2008;117:3088-3098.
9. Nigro P, Satoh K, O'Dell MR, Soe NN, Cui Z, Mohan A, Abe J, Alexis JD, Sparks JD, Berk BC. Cyclophilin A is an infammatory mediator that promotes atherosclerosis in apolipoprotein E-defcient mice. J Exp Med. 2011;208:53-66.
10. Taguchi I, Abe S, Inoue T. Cyclophilin A is a promising predictor of coronary artery disease. Circ J. 2013;77:321-322.
11. Zuern CS, Müller KA, Seizer P, Geisler T, Banya W, Klingel K, Kandolf R, Bauer A, Gawaz M, May AE. Cyclophilin A predicts clinical outcome in patients with congestive heart failure undergoing endomyocardial biopsy. Eur J Heart Fail. 2013;15:176-184.
12. Satoh K, Fukumoto Y, Sugimura K, et al. Plasma cyclophilin A is a novel biomarker for coronary artery disease. Circ J. 2013;77:447-455.
13. Biancone L, Bowen MA, Lim A, Aruffo A, Andres G, Stamenkovic I. Identifcation of a novel inducible cell-surface ligand of CD5 on activated lymphocytes. J Exp Med. 1996;184:811-819.
14. Arai S, Shelton JM, Chen M, Bradley MN, Castrillo A, Bookout AL, Mak PA, Edwards PA, Mangelsdorf DJ, Tontonoz P, Miyazaki T. A role for the apoptosis inhibitory factor AIM/Spalpha/Api6 in atherosclerosis development. Cell Metab. 2005;1:201-213.
15. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277-285.
16. Moulton KS, Olsen BR, Sonn S, Fukai N, Zurakowski D, Zeng X. Loss of collagen XVIII enhances neovascularization and vascular permeability in atherosclerosis. Circulation. 2004;110:1330-1336.
17. Santos JL, Saus E, Smalley SV, Cataldo LR, Alberti G, Parada J, Gratacòs M, Estivill X. Copy number polymorphism of the salivary amylase gene: implications in human nutrition research. J Nutrigenet Nutrigenomics. 2012;5:117-131.
18. Hochepied T, Berger FG, Baumann H, Libert C. Alpha(1)-Acid glycopro-tein: an acute phase protein with infammatory and immunomodulating properties. Cytokine Growth Factor Rev. 2003;14:25-34.
19. Fournier T, Medjoubi-N N, Porquet D. Alpha-1-Acid glycoprotein. Biochim Biophys Acta. 2000;1482:157-171.
20. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol. 1999;19:330-335.
21. Sentí M, Tomás M, Vila J, Marrugat J, Elosua R, Sala J, Masiá R. Relationship of age-related myocardial infarction risk and Gln/Arg 192 variants of the human paraoxonase1 gene: the REGICOR study. Atherosclerosis. 2001;156:443-449.
22. Li J, Wang X, Huo Y, Niu T, Chen C, Zhu G, Huang Y, Chen D, Xu X. PON1 polymorphism, diabetes mellitus, obesity, and risk of myocardial infarction: Modifying effect of diabetes mellitus and obesity on the association between PON1 polymorphism and myocardial infarction. Genet Med. 2005;7:58-63.
23. Morray B, Goldenberg I, Moss AJ, Zareba W, Ryan D, McNitt S, Eberly SW, Glazko G, Mathew J. Polymorphisms in the paraoxonase and endo-thelial nitric oxide synthase genes and the risk of early-onset myocardial infarction. Am J Cardiol. 2007;99:1100-1105.
24. Bhattacharyya T, Nicholls SJ, Topol EJ, Zhang R, Yang X, Schmitt D, Fu X, Shao M, Brennan DM, Ellis SG, Brennan ML, Allayee H, Lusis AJ, Hazen SL. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA. 2008;299:1265-1276.
25. Nielsen H, Clemmensen I, Kharazmi A. Tetranectin: a novel secretory protein from human monocytes. Scand J Immunol. 1993;37:39-42.
26. Mogues T, Etzerodt M, Hall C, Engelich G, Graversen JH, Hartshorn KL. Tetranectin Binds to the Kringle 1-4 Form of Angiostatin and Modifes Its Functional Activity. J Biomed Biotechnol. 2004;2004:73-78.
27. Kamper EF, Kopeikina L, Mantas A, Stefanadis C, Toutouzas P, Stavridis J. Tetranectin levels in patients with acute myocardial infarction and their alterations during thrombolytic treatment. Ann Clin Biochem. 1998;35 (Pt 3):400-407.